Corum, Duygu DurnaCorum, OrhanTerzi, ErtugrulCoskun, DevranBilen, SonerCetin, GulUney, Kamil2024-12-242024-12-2420220140-77831365-2885https://doi.org/10.1111/jvp.13091https://hdl.handle.net/20.500.12604/7150This study aimed to determine the pharmacokinetics and bioavailability of cefquinome in rainbow trout (Oncorhynchus mykiss) following intravascular (IV), intraperitoneal (IP), and oral (PO) administrations at 14 +/- 1 degrees C. In this study, three hundred and six clinically healthy rainbow trout (110-140 g) were used. The fish received single IV, IP, and PO injections of cefquinome at 10 mg/kg dose. The plasma concentrations of cefquinome were measured using HPLC-UV and were evaluated using non-compartmental analysis. Cefquinome was measured up to 96 h for PO route and 144 h for IV and IP routes in plasma. Following IV administration, t(1/2 lambda z), Cl-T, and V-dss were 18.85 h, 0.037 L/h/kg, and 0.84 L/kg, respectively. The C-max of IP and PO routes was 9.75 and 1.64 mu g/ml, respectively. The bioavailability following IP and PO administrations was 59.46% and 12.33%, respectively. Cefquinome at 10 mg/kg dose may maintain T > MIC above 40% at 72 and 96 h intervals, respectively, following the IP and IV routes for bacteria with MIC values of <= 2 mu g/ml and at 24 h intervals following the PO route for bacteria with MIC value of <= 0.75 mu g/ml. However, further studies are needed to determine in vitro and in vivo antibacterial efficacy and multiple dosage regimens of cefquinome against pathogens isolated from rainbow trout.eninfo:eu-repo/semantics/closedAccessbioavailabilitycefquinomepharmacokineticsrainbow troutArticle456578583Q2WOS:000846697300001Q12-s2.0-851364655303600046110.1111/jvp.13091